tradingkey.logo

Stoke Therapeutics Inc <STOK.OQ> expected to post a loss of 43 cents a share - Earnings Preview

ReutersMay 2, 2025 2:18 PM
  • Stoke Therapeutics Inc STOK.OQ STOK.O is expected to show a rise in quarterly revenue when it reports results on May 5 (estimated) for the period ending March 31 2025

  • The Bedford Massachusetts-based company is expected to report a 80.6% increase in revenue to $7.614 million from $4.22 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Stoke Therapeutics Inc is for a loss of 43 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had risen by about 2.0% in the last three months. ​

  • Wall Street's median 12-month price target for Stoke Therapeutics Inc is $21.00​, above​ its last closing price of $9.87. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.52

-0.53

-0.18

Beat

65.9

Sep. 30 2024

-0.53

-0.53

-0.47

Beat

11.8

Jun. 30 2024

-0.56

-0.56

-0.46

Beat

17.9​

Mar. 31 2024

-0.61

-0.61

-0.57

Beat

6.6

​​Dec. 31 2023

-0.48

-0.63

-0.60

Beat

4.8

Sep. 30 2023

-0.64

-0.63

-0.55

Beat

12.4​

Jun. 30 2023

-0.62

-0.64

-0.69

Missed

-8.4

Mar. 31 2023

-0.68

-0.70

-0.53

Beat

23.9

This summary was machine generated May 2 at 14:18 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI